Patient characteristics
| Presenting white blood count (×109/l) | FAB type | TAM1-151 | Prodrome1-152 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| < 10 | 10-50 | > 50 | M7 | Other | |||||||
| Down’s syndrome patients by age at presentation | |||||||||||
| 2 months or younger (n = 7) | 0 | 4 (57) | 3 (43) | 7 (100) | 0 | ||||||
| 12 months or older (n = 52) | 37 (71) | 10 (19) | 4 (8) | 29 (56) | 23 (44) | 5 (10) | 17 (33) | ||||
| AML10 patients younger than 4 years | |||||||||||
| Down’s syndrome (group A, n = 23)1-153 | 15 (65) | 6 (26) | 2 (9)1-165 | 15 (65) | 8 (35)1-165 | 3 (13) | 10 (43)1-165 | ||||
| Non-Down’s syndrome (n = 114) | 30 (26) | 53 (46) | 30 (26) | 15 (13) | 98 (86) | 3 (3) | |||||
Values are n (%).
↵1-151 Previous, resolved, abnormal blood count in the neonatal period.
↵1-152 Abnormal blood count for at least four weeks before developing true AML.
↵1-153 One child with Down’s syndrome in the AML 10 trial is older than 4 years and is excluded from this particular table and analysis.
↵1-165 p < 0.001; p values are for the Mantel-Haenszel test (trend in presenting white blood count) and Fisher’s exact test (incidence of FAB type), Down’s syndrome children on AML 10 compared with non-Down’s syndrome controls.
AML, acute myeloid leukaemia; FAB, Franco–American–British criteria; TAM, transient abnormal myelopoesis.